Antiviral therapy

Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC

What is claimed is: 
     
         1 . A combination comprising a compound of formula (II) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and lamivudine or a pharmaceutically acceptable salt thereof , wherein the combination is administered simultaneously or sequentially. 
       
     
     
         2 . A combination according to  claim 1  wherein the pharmaceutically acceptable salt of a compound of formula (II) is a sodium salt. 
     
     
         3 . A combination according to  claim 1  wherein the pharmaceutically acceptable salt of rilpivirine is a hydrochloride salt. 
     
     
         4 . A method of treatment of HIV infection comprising administering to a human, a compound of formula (II) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and lamivudine or a pharmaceutically acceptable salt thereof. 
       
     
     
         5 . A method according to  claim 4  wherein the pharmaceutically acceptable salt of a compound of formula (II) is a sodium salt. 
     
     
         6 . A method according to  claim 4  wherein the pharmaceutically acceptable salt of a lamivudine is a hydrochloride salt. A pharmaceutical composition comprising a compound of formula (II) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and lamivudine or a pharmaceutically acceptable salt thereof. 
       
     
     
         8 . A pharmaceutical composition according to claim  7  wherein the pharmaceutically acceptable salt of a compound of formula (II) is a sodium salt. 
     
     
         9 . A pharmaceutical composition according to claim  7  wherein the pharmaceutically acceptable salt of lamivudine is a hydrochloride salt. 
     
     
         10 . A method of treatment according to  claim 4  wherein the compound of formula (II) and lamivudine are administered simultaneously. 
     
     
         11 . A method of treatment according to  claim 4  wherein the compound of formula (II) and lamivudine are administered sequentially. 
     
     
         12 . Use of a combination according to  claims 4  in the preparation of a medicament for the treatment of HIV infection.